



# Celebrex Prior Authorization of Benefits Form

**CONTAINS CONFIDENTIAL PATIENT INFORMATION**

**Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-474-3341.**

**1. Patient information**

**2. Physician information**

Patient name: _____ Patient ID #: _____ Patient DOB: _____ Date of Rx: _____ Patient phone #: _____ Patient email address: _____	Prescribing physician: _____ Physician address: _____ Physician phone #: _____ Physician fax #: _____ Physician specialty: _____ Physician DEA: _____ Physician NPI #: _____ Physician email address: _____
---	--

**3. Medication**

**4. Strength**

**5. Directions**

**6. Quantity per 30 days**

Celebrex	<input type="checkbox"/> 50mg <input type="checkbox"/> 100mg <input type="checkbox"/> 200mg <input type="checkbox"/> 400mg	_____	Specify: _____
----------	---	-------	----------------

**7. Diagnosis:** \_\_\_\_\_

**8. Approval criteria:** (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)

Patient's age: \_\_\_\_\_

Yes  No Patient has a diagnosis of FAP or ankylosing spondylitis in the last 730 days.

Yes  No Patient has a diagnosis of PUD or GI bleed in the last 730 days.

Yes  No Patient has a history of warfarin therapy for 30 days in the last 45 days.

Yes  No Patient has a history of corticosteroid therapy for greater than or equal to 35 days in the last 90 days.

Yes  No Patient has taken high dose NSAID therapy for 30 days in the last 45 days.

Yes  No Patient has a diagnosis of RA, JRA, or OA in the last 730 days.

Yes  No Patient has a history of a DMARD agent for 30 days in the last 60 days.

[provider.wellpoint.com/tx/](https://provider.wellpoint.com/tx/)

Medicaid services provided by Wellpoint Insurance Company to members in the Medicaid Rural Service Area and the STAR Kids program and Wellpoint Texas, Inc. to all other Wellpoint members in Texas. Medicare services provided by Wellpoint Texas, Inc. or Wellpoint Insurance Company.

- |  |  |
|--|--|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient has a history of 2 or more NSAID agents for 30 days in the last 180 days                         |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient has failed a 30-day treatment trial with at least 1 preferred agent(s) within the past 180 days. |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient has a documented allergy or contraindication to preferred agents in this class.                  |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient is being treated for stage-four advanced, metastatic cancer and associated conditions.           |

For the *Texas Medicaid Preferred Drug List*, please refer to the Texas Medicaid Vendor Drug Program website at <https://www.txvendordrug.com/formulary/prior-authorization/preferred-drugs>.

### 9. Physician signature

\_\_\_\_\_  
Prescriber or authorized signature

\_\_\_\_\_  
Date

*Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations and exclusions. The submitting provider certifies that the information provided is true, accurate and complete and the requested services are medically indicated and necessary to the health of the patient.*

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.